Federated Hermes’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.15M | Sell |
8,728
-40
| -0.5% | -$5.31K | ﹤0.01% | 1084 |
|
|
2025
Q4 | $1.24M | Sell |
8,768
-2,062
| -19% | -$299K | ﹤0.01% | 1072 |
|
|
2025
Q3 | $1.52M | Buy |
10,830
+1,591
| +17% | +$216K | ﹤0.01% | 1015 |
|
|
2025
Q2 | $1.16M | Sell |
9,239
-202
| -2% | -$23.2K | ﹤0.01% | 1092 |
|
|
2025
Q1 | $1.04M | Sell |
9,441
-25,402
| -73% | -$3.22M | ﹤0.01% | 1089 |
|
|
2024
Q4 | $4.76M | Sell |
34,843
-54,079
| -61% | -$6.69M | 0.01% | 726 |
|
|
2024
Q3 | $10.2M | Sell |
88,922
-22,133
| -20% | -$3.03M | 0.02% | 568 |
|
|
2024
Q2 | $15.3M | Buy |
111,055
+3,818
| +4% | +$524K | 0.04% | 458 |
|
|
2024
Q1 | $14.8M | Sell |
107,237
-1,340
| -1% | -$183K | 0.03% | 481 |
|
|
2023
Q4 | $14.3M | Sell |
108,577
-1,685
| -2% | -$194K | 0.04% | 471 |
|
|
2023
Q3 | $12.4M | Buy |
110,262
+12,815
| +13% | +$1.35M | 0.03% | 483 |
|
|
2023
Q2 | $9.19M | Buy |
97,447
+16,986
| +21% | +$1.66M | 0.02% | 560 |
|
|
2023
Q1 | $8.14M | Buy |
80,461
+43,249
| +116% | +$4.5M | 0.02% | 595 |
|
|
2022
Q4 | $4.44M | Buy |
37,212
+22,066
| +146% | +$2.58M | 0.01% | 708 |
|
|
2022
Q3 | $1.61M | Sell |
15,146
-1,695
| -10% | -$172K | ﹤0.01% | 979 |
|
|
2022
Q2 | $1.64M | Sell |
16,841
-16,269
| -49% | -$1.5M | ﹤0.01% | 985 |
|
|
2022
Q1 | $3.1M | Sell |
33,110
-4,570
| -12% | -$387K | 0.01% | 902 |
|
|
2021
Q4 | $3.21M | Sell |
37,680
-1,975
| -5% | -$182K | 0.01% | 940 |
|
|
2021
Q3 | $3.8M | Sell |
39,655
-23,890
| -38% | -$2.26M | 0.01% | 888 |
|
|
2021
Q2 | $6.18M | Sell |
63,545
-86,225
| -58% | -$8.26M | 0.01% | 786 |
|
|
2021
Q1 | $14.6M | Buy |
149,770
+149,720
| +299,440% | +$15.7M | 0.03% | 569 |
|
|
2020
Q4 | $5K | Sell |
50
-89,533
| -100% | -$8.65M | ﹤0.01% | 2057 |
|
|
2020
Q3 | $8.61M | Buy |
89,583
+40,651
| +83% | +$4.7M | 0.02% | 602 |
|
|
2020
Q2 | $5.97M | Buy |
48,932
+22,432
| +85% | +$2.48M | 0.01% | 669 |
|
|
2020
Q1 | $2.29M | Sell |
26,500
-6,058
| -19% | -$593K | 0.01% | 849 |
|
|
2019
Q4 | $3.5M | Buy |
32,558
+24,047
| +283% | +$2.52M | 0.01% | 871 |
|
|
2019
Q3 | $767K | Sell |
8,511
-642
| -7% | -$60K | ﹤0.01% | 1360 |
|
|
2019
Q2 | $773K | Sell |
9,153
-677
| -7% | -$55.6K | ﹤0.01% | 1357 |
|
|
2019
Q1 | $866K | Sell |
9,830
-115,670
| -92% | -$9.67M | ﹤0.01% | 1343 |
|
|
2018
Q4 | $8.96M | Sell |
125,500
-26,988
| -18% | -$2.59M | 0.02% | 535 |
|
|
2018
Q3 | $18.7M | Buy |
152,488
+72,224
| +90% | +$8.19M | 0.04% | 374 |
|
|
2018
Q2 | $7.89M | Sell |
80,264
-65,789
| -45% | -$5.89M | 0.02% | 543 |
|
|
2018
Q1 | $12.1M | Buy |
146,053
+16,392
| +13% | +$1.38M | 0.04% | 378 |
|
|
2017
Q4 | $10.1M | Buy |
129,661
+5,007
| +4% | +$342K | 0.03% | 430 |
|
|
2017
Q3 | $7.64M | Buy |
124,654
+1,097
| +0.9% | +$57.9K | 0.02% | 458 |
|
|
2017
Q2 | $5.68M | Buy |
+123,557
| New | +$5.99M | 0.02% | 538 |
|
|
2016
Q1 | – | Sell |
-1,958
| Closed | -$111K | – | 2149 |
|
|
2015
Q4 | $111K | Sell |
1,958
-11,816
| -86% | -$601K | ﹤0.01% | 1560 |
|
|
2015
Q3 | $548K | Sell |
13,774
-2,174
| -14% | -$105K | ﹤0.01% | 1259 |
|
|
2015
Q2 | $762K | Buy |
15,948
+5,948
| +59% | +$252K | ﹤0.01% | 1234 |
|
|
2015
Q1 | $397K | Buy |
+10,000
| New | +$358K | ﹤0.01% | 1418 |
|
Other funds holding NBIX
VPM
VCM
Federated Hermes's NBIX Position: Q1 2026 in Review
Federated Hermes reduced its Neurocrine Biosciences (NBIX) stake by 0.46% in Q1 2026, selling an estimated $5.31K and leaving 8,728 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1084.
Federated Hermes first reported a position in NBIX in Q1 2015 and has held it in 40 quarters since. The position peaked at $18.7M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Federated Hermes held 8,728 shares of Neurocrine Biosciences worth $1.15M as of Q1 2026.
- Federated Hermes sold 40 Neurocrine Biosciences shares in Q1 2026, an estimated $5.31K.
- Neurocrine Biosciences made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1084 holding.
- Federated Hermes first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 40 quarters since.
- Federated Hermes's Neurocrine Biosciences position peaked at $18.7M in Q3 2018.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.